 |
|
Application of Microarrays to Neurological Disease
Lisa-Marie Sturla, PhD;
Ana Fernandez-Teijeiro, MD, PhD;
Scott L. Pomeroy, MD, PhD
Arch Neurol. 2003;60:676-682.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
Modern microarray-based functional genomics holds great promise for revealing novel molecular and cellular mechanisms of disease. First introduced commercially in 1996, microarrays have been used widely to monitor the expression of thousands of genes in biological samples, as described in the following paragraphs. Other microarray-based genomic applications are also in development, including comparative genomic hybridization, on-chip sequencing, and novel drug discovery. For example, DNA array-based comparative genomic hybridization identifies chromosomal gains and losses with greatly improved resolution compared with conventional methods that use metaphase chromosomes as hybridization targets.1 This increase in resolution will continue to improve as the technology advances. Moreover, microarrays provide a better platform for automation than is possible with standard metaphase techniques. Where genetic mutations and aberrations are already well characterized, microarrays can be customized to be effectively used as a diagnostic and prognostic tool.2-3 . . . [Full Text of this Article]
METHODS
UNSUPERVISED Principal Component Analysis Self-organizing Maps SUPERVISED k-Nearest Neighbors Weighted Voting Support Vector Machines
COMMENT
RELEVANCE TO THE STUDY OF NEUROSCIENCE AND THE PRACTICE OF NEUROLOGY CONCLUSIONS USEFUL WEB SITES
From the Division of Neuroscience, Department of Neurology, Children's Hospital, Harvard Medical School, Boston, Mass (Drs Sturla, Fernandez-Teijeiro, and Pomeroy); and the Unidad de Oncologia Pediatrica, Hospital de Cruces-Baracaldo, Basque Country, Spain (Dr Fernandez-Teijeiro).
|
